The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib was developed by the experts of the Russian Association of Endocrinologists and the Russian Society of Clinical Oncology. The consensus contains recommendation o...
Saved in:
Main Authors: | Natalya V. Mazurina, Elena V. Artamonova, Maria F. Beloyartseva, Ekaterina I. Volkova, Inna P. Ganshina, Ekaterina A. Troshina, Sergey A. Tjulandin, Viacheslav A. Chubenko |
---|---|
Format: | article |
Language: | RU |
Published: |
IP Habib O.N.
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/95b6d9b471d74d51ad5bf1e4d91f076f |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
by: Armaghani AJ, et al.
Published: (2020) -
The frequency and spectrum of PIK3CA mutations in patients with estrogen receptor-positive HER2-negative advanced breast cancer residing in various regions of Russia
by: Tatiana N. Sokolova, et al.
Published: (2021) -
Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives
by: Chang DY, et al.
Published: (2021) -
The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review
by: Irina V. Poddubnaya, et al.
Published: (2021) -
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
by: Editorial Board
Published: (2021)